Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Overall and disease-free survival outcomes of patients receiving intensity-modulated radiation therapy (IMRT) with PET-CT-based planning for cancers of the head and neck

Overall and disease-free survival outcomes of patients receiving intensity-modulated radiation... AbstractIntroductionCombined modality treatment regimens have provided modest gains in locoregional control rates of cancers of the head and neck (HNC), and intensity-modulated radiation therapy (IMRT) has gained widespread use. The methodology for determining contours of the gross tumour volume (GTV) in the radiation treatment plan is often based on combined anatomic and metabolic data from positron emission tomography–computed tomography (PET-CT). This study aimed to retrospectively evaluate the overall survival and disease-free survival outcomes of patients with HNC who received definitive IMRT with or without chemotherapy, planned with PET-CT.Materials and MethodsA total of 1,200 patients underwent treatment for HNC during the study period, from 1 January 2002 to 31 December 2010. Of those, 261 cases had evaluable data that met the inclusion criteria for the study. The incidence and timing of locoregional recurrence, distant metastatic disease, new primary malignancies and death were evaluated retrospectively. Overall and disease-free survival (survival to time of first recurrence) were determined by the life table method. Incidence of distance metastatic disease and additional cancers were also studied.ResultsMedian follow-up from treatment initiation was 26·4 months (range 1·2–84·7 months). Overall survival and disease-free survival rates were 0·883 and 0·791, respectively, at 1 year; 0·793 and 0·688, respectively, at 2 years; and 0·732 and 0·619, respectively, at 3 years. The cumulative risk of recurrence was 22·6% at 3 years following definitive IMRT and the median time to recurrence was 345 days. There was an overall low incidence of distant metastatic disease (3·07%) and additional cancers (8·05%).ConclusionOverall and disease-free survival outcomes of a large cohort of HNC patients treated with definitive IMRT radiotherapy following treatment planning with PET-CT shows a similar high level of disease control and mortality rate as previously published outcome studies of shorter terms and/or smaller numbers of patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Radiotherapy in Practice Cambridge University Press

Overall and disease-free survival outcomes of patients receiving intensity-modulated radiation therapy (IMRT) with PET-CT-based planning for cancers of the head and neck

Journal of Radiotherapy in Practice , Volume 14 (3): 11 – Apr 30, 2015
Download PDF
11 pages

Loading next page...
 
/lp/cambridge-university-press/overall-and-disease-free-survival-outcomes-of-patients-receiving-9kJmgbBhF3

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Cambridge University Press
Copyright
© Cambridge University Press 2015 
ISSN
1467-1131
eISSN
1460-3969
DOI
10.1017/S1460396915000187
Publisher site
See Article on Publisher Site

Abstract

AbstractIntroductionCombined modality treatment regimens have provided modest gains in locoregional control rates of cancers of the head and neck (HNC), and intensity-modulated radiation therapy (IMRT) has gained widespread use. The methodology for determining contours of the gross tumour volume (GTV) in the radiation treatment plan is often based on combined anatomic and metabolic data from positron emission tomography–computed tomography (PET-CT). This study aimed to retrospectively evaluate the overall survival and disease-free survival outcomes of patients with HNC who received definitive IMRT with or without chemotherapy, planned with PET-CT.Materials and MethodsA total of 1,200 patients underwent treatment for HNC during the study period, from 1 January 2002 to 31 December 2010. Of those, 261 cases had evaluable data that met the inclusion criteria for the study. The incidence and timing of locoregional recurrence, distant metastatic disease, new primary malignancies and death were evaluated retrospectively. Overall and disease-free survival (survival to time of first recurrence) were determined by the life table method. Incidence of distance metastatic disease and additional cancers were also studied.ResultsMedian follow-up from treatment initiation was 26·4 months (range 1·2–84·7 months). Overall survival and disease-free survival rates were 0·883 and 0·791, respectively, at 1 year; 0·793 and 0·688, respectively, at 2 years; and 0·732 and 0·619, respectively, at 3 years. The cumulative risk of recurrence was 22·6% at 3 years following definitive IMRT and the median time to recurrence was 345 days. There was an overall low incidence of distant metastatic disease (3·07%) and additional cancers (8·05%).ConclusionOverall and disease-free survival outcomes of a large cohort of HNC patients treated with definitive IMRT radiotherapy following treatment planning with PET-CT shows a similar high level of disease control and mortality rate as previously published outcome studies of shorter terms and/or smaller numbers of patients.

Journal

Journal of Radiotherapy in Practice – Cambridge University Press

Published: Apr 30, 2015

Keywords: head and neck cancer; intensity-modulated radiation therapy (IMRT); PET-CT; survival

References

  • PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response
  • Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study
  • FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma
  • Hybrid PET-CT simulation for radiation treatment planning in head and neck cancers: a brief technical report
  • Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma
  • PET/CT staging followed by intensity-modulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison
  • The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma
  • FDG-PET in radiotherapy treatment planning of advanced head and neck cancer—a prospective clinical analysis
  • Efficacy of FDG-PET for defining gross tumor volume of head and neck cancer
  • Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a ‘Big Brother’ evaluation
  • Topographic metabolic map of head and neck squamous cell carcinoma using 18F-FDG PET and CT image fusion
  • Thresholding in PET images of static and moving targets
  • Can positron emission tomography (PET) or PET/computed tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT?
  • Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers
  • Base-of-tongue cancer: survival, function, and quality of life after external-beam irradiation and brachytherapy
  • Improved survival using intensity-modulated radition therapy in head and neck cancers
  • A phase III trial to test accelerated (AFX) versus standard (SFX) fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of efficacy and toxicity
  • Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials
  • Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation
  • Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer
  • Initial results of hypoxia imaging using 1-alpha-D-(5-deoxy-5-[18F]-fluoroarabinofuranyosyl)-2-nitroimidazole (18F-FAZA)
  • 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors
  • Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome
  • Molecular PET imaging for biology-guided adaptice radiotherapy of head and neck cancer